Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B and pulmonary surfactant

M Griese1, A Schams, K P Lohmeier

  • 1The Lung Research Group, Kinderpoliklinik, Ludwig-Maximilians-University, Pettenkoferstr 8a, D-80336 Munich, Germany. griese@pk-i.med.uni-muenchen.de

European Journal of Medical Research
|August 26, 1998
PubMed
Summary

Amphotericin B formulations can impact lung surfactant function. Amphotericin B deoxycholate and deoxycholic acid inhibited surfactant activity, while liposomal amphotericin B had minimal effects, suggesting careful consideration for intrapulmonary drug delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary interstitial glycogenosis - A systematic analysis of new cases.

Respiratory medicine·2018
Same author

[Not Available].

MMW Fortschritte der Medizin·2016
Same author

[Not Available].

MMW Fortschritte der Medizin·2016
Same author

Niemann-Pick Type C-2 Disease: Identification by Analysis of Plasma Cholestane-3β,5α,6β-Triol and Further Insight into the Clinical Phenotype.

JIMD reports·2015
Same author

Neonatal respiratory insufficiency caused by an (homozygous) ABCA3-stop mutation: a systematic evaluation of therapeutic options.

Klinische Padiatrie·2014
Same author

Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine.

Journal of perinatology : official journal of the California Perinatal Association·2013

Area of Science:

  • Pulmonary medicine
  • Pharmacology
  • Biochemistry

Background:

  • Targeted intrapulmonary drug delivery aims to enhance efficacy and reduce systemic toxicity.
  • Inhaled medications can potentially disrupt pulmonary surfactant function, crucial for lung mechanics.
  • Amphotericin B is used for pulmonary aspergillosis, but its effect on surfactant is unknown.

Purpose of the Study:

  • To investigate the effects of amphotericin B formulations on lung surfactant activity.
  • To assess the potential for drug-induced interference with surfactant function during intrapulmonary therapy.

Main Methods:

  • Pulsating bubble surfactometry was used to measure surface activity.
  • Evaluated pure amphotericin B, amphotericin B deoxycholate (Fungizone), deoxycholic acid, and liposomal amphotericin B (Ambisome).

Related Experiment Videos

  • Tested effects on natural surfactant and a lipid-extracted surfactant (Survanta).

    • Main Results:

    • Pure amphotericin B did not affect surfactant preparations.
    • Amphotericin B deoxycholate and deoxycholic acid dose-dependently inhibited surfactant surface activity and perturbed lipid organization.
    • Liposomal amphotericin B (Ambisome) showed only marginal effects on surfactant function.

    Conclusions:

    • The formulation of amphotericin B is critical when considering intrapulmonary delivery.
    • Amphotericin B deoxycholate's potential to disrupt lung surfactant function requires careful consideration for high-dose intrapulmonary administration.
    • Liposomal formulations may offer a safer alternative regarding surfactant interactions for inhaled amphotericin B therapy.